Each vial contains 20ml solution containing Oxaliplatin USP 100mg (5mg/ml).
Oxaliplatin, used in combination with infusional 5-fluorouracil/folinic acid, is indicated for: • Adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. • Treatment of advanced colorectal cancer.
Each vial contains 20ml solution containing Oxaliplatin USP 100mg (5mg/ml).
Oxaliplatin, used in combination with infusional 5-fluorouracil/folinic acid, is indicated for: • Adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. • Treatment of advanced colorectal cancer.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.